AI Summary
✦ ClarthaPrice Forecast
Probabilistic Range
Probabilistic lognormal cone using 1Y realized volatility and analyst-target drift when available.
Revenue Forecast
₹ CrEPS Forecast
₹ / shareMulti-factor synthesis of 5 key dimensions
From 2 analysts
Fundamentals
Fundamentals institutional score is 87 using EVA spread proxy 7.9%; growth durability 82.1.
Valuation
Valuation institutional score is 9 using relative multiple z-scores where peer dispersion is available.
Analyst Consensus
Analyst View institutional score is 33 using mean target upside -5.0%; dispersion penalty 5.9; recommendation breadth from available consensus.
Technical Structure
Technicals institutional score is 91 using EMA-20 continuation within 5% tolerance; VCP range/volume contraction proxy.
Market Sentiment
This data source has not been supplied for the decision payload.
Signal Summary
Market intelligence remains Neutral. fundamentals and technical structure provide support, while valuation and analyst consensus remain considerations.
Composite weights: Fundamentals 25%, Valuation 20%, Analyst Consensus 20%, Technical Structure 20%, Market Sentiment 15%.
Key Data Points
Important Note: This is market intelligence, not investment advice. Always conduct your own research and consider your financial goals and risk tolerance.
Valuation Metrics
Trading 42.0% above historical median. Valuation is stable — currently in the strongly overvalued zone (z-score: +2.08). Confidence: 77%.
Live forward EPS implies next-12-month EPS of ₹106.95. Applying the stock's normalized valuation corridor produces a fair range of ₹1,805.32 to ₹2,576.43, with base value near ₹2,359.32 (-10.5% vs current price).
Live forward estimate anchored to the company's historical valuation corridor.
Forward EPS
₹106.95
Forward P/E
24.6x
Base Fair Value
₹2,359.32
Fair Range
₹1,805.32 - ₹2,576.43
Upside To Base
-10.5%
Estimate Source
Live forward EPS
Growth Estimate
+19.4%
5Y Average
16.50
Current
31.32
Overvalued
24.09
Undervalued
16.88
5Y Average
13.20
Current
25.05
Overvalued
18.25
Undervalued
7.23
5Y Average
4.83
Current
9.16
Overvalued
6.68
Undervalued
2.64
Peers & Comparison
Sector: Health Care · Theme: Pharmaceuticals
| Company | Rev. Growth | Margin | P/E | vs Avg | 52W Perf. |
|---|---|---|---|---|---|
ALIVUS LIFE SCIENCES LTD ALIVUSPharmaceuticals | +6.4% | 23.3% | 27.9x Undervalued | -35% vs avg | +43.2% |
AKUMS DRUGS AND PHARMA L AKUMSPharmaceuticals | +9.6% | 5.9% | 44.4x Fair | +3% vs avg | +51.8% |
GLENMARK PHARMACEUTICALS GLENMARKPharmaceuticals | +23.1% | 10.1% | 35.6x Undervalued | -17% vs avg | +9.4% |
ABBOTT INDIA LIMITED ABBOTINDIAPharmaceuticals | +6.5% | 22.4% | 37.6x Fair | -12% vs avg | -15.4% |
AJANTA PHARMA LIMITED AJANTPHARMPharmaceuticals | +24.8% | 19.6% | 38.7x Fair | -10% vs avg | +30.0% |
IPCA LABORATORIES LTD IPCALABPharmaceuticals | +6.3% | 11.8% | 38.8x Fair | -10% vs avg | +22.5% |
LAURUS LABS LIMITED LAURUSLABSPharmaceuticals | +29.1% | 15.0% | 90.6x Premium | +111% vs avg | +123.1% |
DR. REDDY S LABORATORIES DRREDDYPharmaceuticals | -5.6% | 10.0% | 29.5x Undervalued | -31% vs avg | -5.0% |
CAPLIN POINT LAB LTD. trades at a discount (31.5x vs peer avg 42.9x), suggesting potential undervaluation relative to the Pharmaceuticals cohort. Peers include ALIVUS LIFE SCIENCES LTD, AKUMS DRUGS AND PHARMA L, GLENMARK PHARMACEUTICALS — selected based on business model, industry classification, market cap similarity, and business theme alignment.
Financials
Real statement data for revenue, earnings quality, conversion, and balance-sheet coverage. Monetary values are shown in Rs crore.
Latest revenue
₹191 CrMar 2026Latest net profit
₹110 CrMar 2026Latest EPS
₹14.41Mar 2026Net margin
44.0%Mar 2026Performance
Bars show revenue and net profit. The line shows net margin.
- Revenue
- Net income
- Net margin %
Earnings
Revenue is shown in crores. EPS is rupees per share.
- Revenue
- EPS
Revenue to profit conversion
Bridge from operating numbers to profit for the latest reported period.
Latest reported period: Mar 2026
Debt level and coverage
Debt, cash and free cash flow compared on the same crore scale.
- Debt
- Free cash flow
- Cash & equivalents
Results
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 145 | 174 | 179 | 133 | 139 | 186 | 208 | 185 | 174 | 183 | 175 | 189 | 191 |
| Expenses + | 80 | 97 | 90 | 70 | 82 | 104 | 110 | 108 | 99 | 96 | 99 | 98 | 108 |
| Operating Profit | 65 | 77 | 89 | 63 | 58 | 81 | 98 | 77 | 75 | 87 | 76 | 92 | 84 |
| OPM % | 45% | 44% | 50% | 48% | 41% | 44% | 47% | 42% | 43% | 47% | 43% | 48% | 44% |
| Other Income + | 12 | 27 | 24 | 18 | 36 | 22 | 43 | 29 | 41 | 32 | 59 | 32 | 61 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 6 | 7 | 7 | 7 | 7 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 7 |
| Profit before tax | 71 | 97 | 107 | 74 | 87 | 97 | 135 | 100 | 110 | 112 | 129 | 117 | 138 |
| Tax % | 23% | 22% | 23% | 26% | 20% | 25% | 21% | 25% | 21% | 24% | 20% | 25% | 20% |
| Net Profit + | 54 | 76 | 82 | 55 | 70 | 73 | 106 | 75 | 86 | 86 | 103 | 87 | 110 |
| EPS in Rs | 7.16 | 10.04 | 10.81 | 7.30 | 9.20 | 9.54 | 13.91 | 9.83 | 11.38 | 11.30 | 13.50 | 11.48 | 14.41 |
| Raw PDF |
All values in ₹ Crores unless otherwise stated. Source: Screener Master (Standalone).
Events Timeline
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Board Meeting Intimation for Approval Of Financial Results And Recommendation Of Final Dividend, If Any.
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018